These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22286735)

  • 1. [Acute encephalopathy associated with the use of intravenous immunoglobulin. Report of one case].
    Soto V A; Cartier R L
    Rev Med Chil; 2011 Oct; 139(10):1340-3. PubMed ID: 22286735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature.
    Mathy I; Gille M; Van Raemdonck F; Delbecq J; Depré A
    Acta Neurol Belg; 1998 Dec; 98(4):347-51. PubMed ID: 9922823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Posterior reversible encephalopathy syndrome during intravenous immunoglobulin therapy in Guillain-Barré syndrome].
    Watanabe E; Ido N; Saito T; Kato H; Terashi H; Aizawa H
    Rinsho Shinkeigaku; 2021 Jan; 61(1):12-17. PubMed ID: 33328417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible Splenial Lesion Syndrome After Intravenous Immunoglobulin Treatment for Guillain-Barre Syndrome.
    Uygur Kucukseymen E; Yuksel B; Genc F; Ozaydin Goksu E; Yildiz S; Bicer Gomceli Y
    Clin Neuropharmacol; 2017; 40(5):224-225. PubMed ID: 28816832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior reversible encephalopathy syndrome associated with IVIG in a patient with Guillain-Barré syndrome.
    Koichihara R; Hamano S; Yamashita S; Tanaka M
    Pediatr Neurol; 2008 Aug; 39(2):123-5. PubMed ID: 18639758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.
    Tsai CP; Wang KC; Liu CY; Sheng WY; Lee TC
    J Clin Neurosci; 2007 Jul; 14(7):625-9. PubMed ID: 17532498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
    Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
    No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posterior reversible encephalopathy syndrome associated with Guillain-Barré syndrome: Case report and clinical management considerations.
    Salvalaggio A; Cagnin A; Marson P; Ferracci F; Cortelli P; Corbetta M; Briani C
    J Clin Apher; 2020 Jun; 35(3):231-233. PubMed ID: 32289176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain-Barré syndrome.
    Odaka M; Tatsumoto M; Hoshiyama E; Hirata K; Yuki N
    Eur Neurol; 2005; 53(4):194-6. PubMed ID: 15970631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
    Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
    Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal failure resulting from intravenous immunoglobulin therapy.
    Wajanaponsan N; Cheng SF
    Hawaii Med J; 2004 Sep; 63(9):266-7. PubMed ID: 15540524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days.
    Raphael JC; Chevret S; Harboun M; Jars-Guincestre MC;
    J Neurol Neurosurg Psychiatry; 2001 Aug; 71(2):235-8. PubMed ID: 11459901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
    Dididze MN
    Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute renal failure following treatment with intravenously administered immunoglobulins].
    van Zanten AR; Beekhuyzen M; van der Meer YG; de Gooijer A; Feith GW
    Ned Tijdschr Geneeskd; 2003 Feb; 147(7):307-10. PubMed ID: 12622009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posterior reversible encephalopathy and Guillain-Barré syndrome in a single patient: coincidence or causative relation?
    Van Diest D; Van Goethem JW; Vercruyssen A; Jadoul C; Cras P
    Clin Neurol Neurosurg; 2007 Jan; 109(1):58-62. PubMed ID: 16487653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional recovery of untreated human immunodeficiency virus-associated Guillain-Barré syndrome: a case report.
    Schreiber AL; Norbury JW; De Sousa EA
    Ann Phys Rehabil Med; 2011 Nov; 54(8):519-24. PubMed ID: 22036304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-dose intravenous immunoglobulins for treatment of optic neuritis in Guillain-Barré syndrome].
    Lüke C; Dohmen C; Dietlein TS; Brunner R; Lüke M; Krieglstein GK
    Klin Monbl Augenheilkd; 2007 Dec; 224(12):932-4. PubMed ID: 18260057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.